Ferdinandos Skoulidis
MD PhD
Associate Professor
👥Biography 个人简介
Ferdinandos Skoulidis has contributed to KRAS-mutant NSCLC biology and treatment, including characterizing KRAS G12C NSCLC molecular subgroups and co-mutation patterns (STK11, KEAP1) that influence immunotherapy and targeted therapy outcomes. His contributions to the CodeBreaK100 trial establishing sotorasib for KRAS G12C-mutant NSCLC and to understanding the molecular context of KRAS-targeted therapy response have been important.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ferdinandos Skoulidis 的研究动态
Follow Ferdinandos Skoulidis's research updates
留下邮箱，当我们发布与 Ferdinandos Skoulidis（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment